Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1387446 +/- Ezabenlimab in Advanced Solid Tumors
NCT04147234Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 1387446 in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Dose-Limiting Toxicities at 3 weeks. Started Aug 2020; status: completed.
02
Drugs
BI 1387446
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04147234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147234.